Security
ARMP · Armata Pharmaceuticals, Inc.
ARMPNYSE_AMERICANCommon stockCurrentCIK 921114Updated Sep 26, 2026
Name history
AmpliPhi Biosciences Corp · through May 8, 2019TARGETED GENETICS CORP /WA/ · through Feb 11, 2011
ARMP price & chart
Loading TradingView…
AMEX:ARMP on TradingView ↗About the company
Armata is a late clinical-stage biotechnology company focused on the development of high-purity and potency, pathogen-specific bacteriophage therapeutics for the treatment of antibiotic-resistant and difficult-to-treat bacterial infections using its proprietary bacteriophage-based technology. Armata is developing and advancing a broad pipeline of natural and synthetic phage candidates, including clinical candidates for Pseudomonas aeruginosa, Staphylococcus aureus, and other important pathogens. Armata is committed to advancing phage therapy with drug development expertise that spans bench to clinic including in-house phage-specific current Good Manufacturing Practices (“cGMP”) manufacturing to support full commercialization.
In the news
No coverage from other publishers is available.
Recent filings
Other Events
Items 8.01, 9.01
Regulation FD Disclosure
Items 7.01, 9.01
10-Q filing
Results of Operations and Financial Condition
Items 2.02, 9.01
Regulation FD Disclosure
Items 7.01, 9.01
Show 5 more recent filings
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements
Items 5.02, 9.01
Regulation FD Disclosure
Items 7.01, 9.01
S-8 filing
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements
Items 5.02
Other Events
Items 8.01, 9.01
Financials
FY 2025 · USDSource
Source
Source
Source
Source
balance sheet · annual statements
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|
| ASSETS | ||||
| AssetsUSD | 76,882,000Source | 86,437,000Source | 98,363,000Source | 95,834,000Source |
| Property, Plant and Equipment, NetUSD | 12,194,000Source | 13,241,000Source | 12,559,000Source | 3,617,000Source |
| GoodwillUSD | 3,490,000Source | 3,490,000Source | 3,490,000Source | 3,490,000Source |
| Intangible Assets, Net (Excluding Goodwill)USD | 10,256,000Source | 10,256,000Source | 10,256,000Source | 10,256,000Source |
| Current assets: | ||||
| Cash and Cash Equivalents, at Carrying ValueUSD | 8,688,000Source | 9,291,000Source | 13,523,000Source | 14,852,000Source |
| Assets, CurrentUSD | 10,668,000Source | 11,308,000Source | 19,151,000Source | 27,047,000Source |
| Prepaid Expense and Other Assets, CurrentUSD | 1,508,000Source | 1,273,000Source | 2,265,000Source | 10,259,000Source |
| Operating Lease, Right-of-Use AssetUSD | 33,911,000Source | 41,687,000Source | 44,717,000Source | 43,035,000Source |
| Other Assets, NoncurrentUSD | 973,000Source | 975,000Source | 2,470,000Source | 2,429,000Source |
| LIABILITIES AND EQUITY | ||||
| LiabilitiesUSD | 295,478,000Source | 134,456,000Source | 130,428,000Source | 59,754,000Source |
| Stockholders’ equity: | ||||
| Common Stock, Value, IssuedUSD | 364,000Source | 362,000Source | 361,000Source | 361,000Source |
| Additional Paid in CapitalUSD | 282,574,000Source | 279,354,000Source | 276,393,000Source | 275,493,000Source |
| Retained Earnings (Accumulated Deficit)USD | -501,534,000Source | -327,735,000Source | -308,819,000Source | -239,774,000Source |
| Stockholders' Equity Attributable to ParentUSD | -218,596,000Source | -48,019,000Source | -32,065,000Source | 36,080,000Source |
| Liabilities and EquityUSD | 76,882,000Source | 86,437,000Source | 98,363,000Source | 95,834,000Source |
| Current liabilities: | ||||
| Liabilities, CurrentUSD | 8,947,000Source | 48,249,000Source | 16,461,000Source | 24,873,000Source |
| Operating Lease, Liability, CurrentUSD | 4,564,000Source | 4,431,000Source | 9,481,000Source | 17,011,000Source |
| Accounts Payable, CurrentUSD | 921,000Source | 766,000Source | 1,585,000Source | 1,678,000Source |
| Operating Lease, Liability, NoncurrentUSD | 26,533,000Source | 27,694,000Source | 28,583,000Source | 31,804,000Source |
| Deferred Income Tax Liabilities, NetUSD | 3,077,000Source | 3,077,000Source | 3,077,000Source | 3,077,000Source |
| Additional Financial Items | ||||
| Deferred Tax Liabilities, NetUSD | 3,077,000Source | 3,077,000Source | 3,077Source | 3,077,000Source |
cash flow · annual statements
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|
| Cash flows from operating activities: | ||||
| Net Income (Loss), Including Portion Attributable to Noncontrolling InterestUSD | -173,799,000Source | -18,916,000Source | -69,045,000Source | -36,917,000Source |
| Adjustments to reconcile net income to net cash provided by operating activities: | ||||
| Depreciation, Depletion and AmortizationUSD | — | 1,325,000Source | 972,000Source | — |
| Share-based Payment Arrangement, Noncash ExpenseUSD | 2,610,000Source | 2,893,000Source | 938,000Source | 3,105,000Source |
| Net Cash Provided by (Used in) Operating ActivitiesUSD | -25,763,000Source | -37,551,000Source | -47,423,000Source | -32,481,000Source |
| Cash flows from investing activities: | ||||
| Net Cash Provided by (Used in) Investing ActivitiesUSD | -542,000Source | -1,879,000Source | -8,134,000Source | -2,211,000Source |
| Payments to Acquire Property, Plant, and EquipmentUSD | 542,000Source | 1,879,000Source | 8,144,000Source | 2,211,000Source |
| Cash flows from financing activities: | ||||
| Payment, Tax Withholding, Share-based Payment ArrangementUSD | 46,000Source | 61,000Source | 43,000Source | — |
| Net Cash Provided by (Used in) Financing ActivitiesUSD | 25,612,000Source | 34,958,000Source | 53,988,000Source | 44,016,000Source |
| Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate EffectUSD | -693,000Source | -4,472,000Source | -1,569,000Source | 9,324,000Source |
| Cash, Cash Equivalents, Restricted Cash and Restricted Cash EquivalentsUSD | 14,078,000Source | 14,771,000Source | 19,243,000Source | 20,812,000Source |
| Additional Financial Items | ||||
| Share-based Payment Arrangement, ExpenseUSD | 2,610,000Source | 2,893,000Source | 938,000Source | 3,105,000Source |
| DepreciationUSD | 1,531,000Source | 1,300,000Source | 1,000,000Source | 892,000Source |
| Gain (Loss) on Disposition of Property Plant Equipment, Excluding Oil and Gas Property and Timber PropertyUSD | — | — | -81,000Source | — |
| Gain (Loss) on Extinguishment of DebtUSD | — | 2,166,000Source | -3,863,000Source | — |
| General and Administrative ExpenseUSD | 12,409,000Source | 13,184,000Source | 11,649,000Source | 7,437,000Source |
| GoodwillUSD | 3,490,000Source | 3,490,000Source | 3,490,000Source | 3,490,000Source |
| Goodwill, Impairment LossUSD | 0Source | 0Source | 0Source | 0Source |
| Impairment of Intangible Assets, Indefinite-lived (Excluding Goodwill)USD | 0Source | 0Source | 0Source | 0Source |
| Investment Income, InterestUSD | — | — | 179,000Source | 29,000Source |
| Net Income (Loss) Attributable to ParentUSD | -173,799,000Source | -18,916,000Source | -69,045,000Source | -36,917,000Source |
| Net Income (Loss) Available to Common Stockholders, BasicUSD | -173,799,000Source | -18,916,000Source | — | — |
| Operating ExpensesUSD | 41,538,000Source | 47,610,000Source | 45,419,000Source | 42,454,000Source |
| Operating Lease, ExpenseUSD | 8,000,000Source | 8,400,000Source | 7,400,000Source | 6,300,000Source |
| Other Nonoperating Income (Expense)USD | -137,165,000Source | 23,520,000Source | -28,155,000Source | 29,000Source |
| Payments of Financing CostsUSD | — | — | — | 500,000Source |
| Proceeds from Issuance of Common StockUSD | — | — | — | 44,391,000Source |
income statement · annual statements
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|
| Operating Income (Loss)USD | -36,634,000Source | -42,436,000Source | -40,890,000Source | -36,946,000Source |
| Other Nonoperating Income (Expense)USD | -137,165,000Source | 23,520,000Source | -28,155,000Source | 29,000Source |
| Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling InterestUSD | -173,799,000Source | -18,916,000Source | -69,045Source | -36,917,000Source |
| Net Income (Loss) Attributable to ParentUSD | -173,799,000Source | -18,916,000Source | -69,045,000Source | -36,917,000Source |
| Earnings Per Share, BasicUSD per share | -4.8Source | -0.52Source | -1.91Source | -1.08Source |
| Earnings Per Share, DilutedUSD per share | -4.8Source | -0.89Source | -1.91Source | -1.08Source |
| Weighted Average Number of Shares Outstanding, Basicshares | 36,239,253Source | 36,160,848Source | 36,075,555Source | 34,294,124Source |
| Weighted Average Number of Shares Outstanding, Dilutedshares | 36,239,253Source | 59,059,971Source | 36,075,555Source | 34,294,124Source |
| Additional Financial Items | ||||
| Current Income Tax Expense (Benefit)USD | — | — | — | 0Source |
| General and Administrative ExpenseUSD | 12,409,000Source | 13,184,000Source | 11,649,000Source | 7,437,000Source |
| Goodwill, Impairment LossUSD | 0Source | 0Source | 0Source | 0Source |
| Income (Loss) from Continuing Operations before Income Taxes, DomesticUSD | -172,964,000Source | -18,020,000Source | -68,182Source | -32,228,000Source |
| Interest ExpenseUSD | — | — | — | 0Source |
| Interest Expense, DebtUSD | — | — | 2,626,000Source | — |
| Investment Income, InterestUSD | — | — | 179,000Source | 29,000Source |
| Net Income (Loss) Available to Common Stockholders, BasicUSD | -173,799,000Source | -18,916,000Source | — | — |
| Operating ExpensesUSD | 41,538,000Source | 47,610,000Source | 45,419,000Source | 42,454,000Source |
| Operating Lease, ExpenseUSD | 8,000,000Source | 8,400,000Source | 7,400,000Source | 6,300,000Source |
Filing attachments
tm2625977d1_ex99-1.htm · 8-K · 2026-09-23
Exhibit 99.1 Armata Pharmaceuticals Receives $3.7 Million in Additional Non-Dilutive Funding from U.S. Department of War to Support Advancement of AP-SA02 Phase 3 Development Initial Phase 3-focused funding to support advancement of AP-SA02 in complicated Staphylococcus aureus bacteremia New commitment is incremental to previously announced DoW funding and expands total non-dilutive support for the AP-SA02 program to $32.4 million LOS ANGELES, Calif., September 23, 2026 - Armata Pharmaceutic…
Read attachment ↗tm2625289d1_ex99-1.htm · 8-K · 2026-09-14
EX-99.1 2 tm2625289d1_ex99-1.htm EXHIBIT 99.1 Exhibit 99.1 Armata Pharmaceuticals Receives U.S. FDA Breakthrough Therapy Designation for AP-SA02 Designation is driven by compelling Phase 2 clinical data in patients with complicated Staphylococcus aureus bacteremia showing AP-SA02 may offer substantial improvement over available therapies Potentially accelerating the path to market for this innovative antibacterial treatment AP-SA02 now holds Breakthrough Therapy, Fast Track and QIDP desi…
Read attachment ↗armp-20260812xex99d1.htm · 8-K · 2026-08-12
EX-99.1 2 armp-20260812xex99d1.htm EX-99.1 Exhibit 99.1 Armata Pharmaceuticals Announces Financial Results for the Second Quarter 2026 and Provides a Corporate Update LOS ANGELES, Calif., August 12, 2026 - Armata Pharmaceuticals, Inc. (NYSE American: ARMP) (“Armata” or the “Company”), a late clinical-stage biotechnology company focused on the development of high-purity, pathogen-specific bacteriophage therapeutics for the treatment of antibiotic-resistant and difficult-to-treat bacterial i…
Read attachment ↗tm2620782d2_ex99-1.htm · 8-K · 2026-07-20
EX-99.1 2 tm2620782d2_ex99-1.htm EXHIBIT 99.1 Exhibit 99.1 Armata Pharmaceuticals Achieves Key Progress Across Clinical, Regulatory and Manufacturing Activities Supporting Planned Phase 3 Initiation of AP-SA02 FDA submissions address all feedback on clinical, CMC, and regulatory topics from the End-of-Phase 2 meeting Four AP-SA02 engineering runs completed; clinical trial material production is the next planned manufacturing step Phase 3 superiority study remains on track to initiate in …
Read attachment ↗tm2620286d1_ex99-1.htm · 8-K · 2026-07-13
EX-99.1 2 tm2620286d1_ex99-1.htm EXHIBIT 99.1 Exhibit 99.1 Armata Pharmaceuticals Receives Agreement from FDA on Initial Pediatric Study Plan for AP-SA02 for the Treatment of Complicated Staphylococcus aureus Bacteremia Fulfills important regulatory milestone for AP-SA02 on the path toward a future BLA and supports expansion into pediatric patients LOS ANGELES, Calif., July 13, 2026 - Armata Pharmaceuticals, Inc. (NYSE American: ARMP) (“Armata” or the “Company”), a late clinical-stage bio…
Read attachment ↗tm2618503d1_ex99-1.htm · 8-K · 2026-06-23
EX-99.1 2 tm2618503d1_ex99-1.htm EXHIBIT 99.1 Exhibit 99.1 Armata Pharmaceuticals Receives $2.5 Million of Additional Non-Dilutive Award Funding from the U.S. Department of Defense to Support AP-SA02 Supports Phase 3 readiness of AP-SA02 Non-dilutive DoD funding totals $28.7M to date LOS ANGELES, Calif., June 23, 2026 -- Armata Pharmaceuticals, Inc. (NYSE American: ARMP) (“Armata” or the “Company”), a late clinical-stage biotechnology company focused on the development of high-purity, pa…
Read attachment ↗